Streetbeat News

Revenues

AGIO

Analysts have mixed views on Alnylam Pharmaceuticals (NASDAQ:AGIO) with recent ratings showing a shift towards somewhat bullish sentiments. The average 12-month price target has decreased by 3.17% to $53.5. Despite positive revenue growth, the company faces challenges with profitability and returns.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 7:00 pm

VIAV

Viavi Solutions (NASDAQ:VIAV) has received mixed analyst ratings over the past three months, with a recent positive shift in average price targets. Analysts have raised and lowered ratings, reflecting diverse perspectives on the company's performance. Viavi faces challenges with declining revenue, low net margins, and below-average returns on equity and assets. However, it maintains a balanced debt approach.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 7:00 pm

CLX

Over the past three months, 9 analysts have shared their insights on Clorox (NYSE:CLX), with opinions ranging from bullish to bearish. The average 12-month price target has increased by 6.09% to $154.89. Clorox has shown a 27.13% revenue growth rate, but faces challenges with a low net margin and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 7:00 pm

OPCH

Option Care Health (NASDAQ:OPCH) has received mixed analyst ratings over the past three months, with a shift towards more bullish sentiments recently. Analysts have lowered their 12-month price targets, with an average target of $33.8, down from $39.00. Despite this, the company shows strong financial performance with significant revenue growth, high net margins, and efficient debt management.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 7:00 pm

TM

Toyota Motor North America reported a 5% decrease in U.S. vehicle sales for October, with a total of 185,929 vehicles sold.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 6:56 pm

ESNT

Essent Group's shares declined following the release of disappointing Q3 earnings and revenue figures.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 6:55 pm

MSFT

CoreWeave, a cloud startup, is positioning itself as a competitor to tech giants like Microsoft, Amazon, and Alphabet. However, Microsoft is a major customer of CoreWeave, planning to spend $10 billion on its data centers for AI models by the end of the decade. This relationship highlights the complex dynamics between competition and collaboration in the tech industry.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2024 | 6:35 pm

X

US Steel reported Q3 earnings with a profit of 56 cents per share, surpassing expectations. Revenue was $3.85 billion, also exceeding forecasts. The company raised its 2024 capex to $2.3 billion due to cost overruns, with plans to reduce it in 2025. Analysts have mixed views, with some concerns about pricing and regulatory issues.

Portfolio Pulse from Henry Khederian

November 01, 2024 | 6:04 pm

IP

International Paper (NYSE:IP) has received mixed analyst ratings, with a recent trend towards bullish sentiment. Analysts have raised price targets, reflecting optimism about the company's future performance. Despite positive revenue growth, International Paper faces challenges with profitability and returns on equity and assets.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 6:02 pm

AME

AMETEK (NYSE:AME) received mixed ratings from 5 analysts, with a majority being bullish. The average 12-month price target increased to $190.8. Analysts have adjusted their ratings and price targets based on recent market conditions and company performance. AMETEK's financials show strong profitability and efficient asset use, with a focus on growth through acquisitions and new product development.

Portfolio Pulse from Benzinga Insights

November 01, 2024 | 6:02 pm